Cited by 118Blood Pressure and Hypertension StudiesHeart Failure Treatment and ManagementSodium Intake and Health

The DOI matches its Crossref record; 43 of the 46 references it cites were found in a registry or an index.

Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial

Open access

Upadhya, Bharathi, Rocco, Michael, Lewis, Cora E., Oparil, Suzanne, Lovato, Laura C., Cushman, William C., Bates, Jeffrey T., Bello, Natalie A., Aurigemma, Gerard, Fine, Lawrence J., Johnson, Karen C., Rodriguez, Carlos J., Raj, Dominic S., Rastogi, Anjay, Tamariz, Leonardo, Wiggers, Alan, Kitzman, Dalane W.·2017·Circulation: Heart Failure

DOI 10.1161/circheartfailure.116.003613PMC PMC5384646

Open this paper in CoChat — free account

Abstract

Background— Acute decompensated heart failure (ADHF) was a frequent common outcome in SPRINT (Systolic Blood Pressure Intervention Trial). We examined whether there was differential reduction in ADHF events from intensive blood pressure [BP] treatment among the 6 key, prespecified subgroups in SPRINT: age ≥75 years, prior cardiovascular disease, chronic kidney disease, women, black race, and 3 levels of baseline systolic BP (≤132 versus >132 to <145 versus ≥145 mm Hg). Methods and Results— ADHF was defined as hospitalization for ADHF, confirmed and formally adjudicated by a blinded events committee using standardized protocols. At 3.29 years follow-up, there were 103 ADHF events (2.2%) among 4683 standard arm participants and 65 ADHF events (1.4%) among 4678 intensive arm participants (Cox proportional hazards ratio, 0.63; 95% confidence interval, 0.46–0.85; P value =0.003). In multivariable analyses, including treatment arm, baseline covariates that were significant predictors for ADHF included chronic kidney disease, cardiovascular disease, age≥75 years, body mass index, and higher systolic BP. The beneficial effect of the intervention on incident ADHF was consistent across all prespecified subgroups. Participants who had incident ADHF had markedly increased risk of subsequent cardiovascular events, including a 27-fold increase ( P <0.001) in cardiovascular death. Conclusions— Targeting a systolic BP<120 mm Hg, compared with <140 mm Hg, significantly reduced ADHF events, and the benefit was similar across all key, prespecified subgroups. Participants who developed ADHF had markedly increased risk for subsequent cardiovascular events and death, highlighting the importance of strategies aimed at prevention of ADHF, especially intensive BP reduction. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01206062

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.116.003613

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Hemodynamic Patterns of Age-Related Changes in Blood Pressure: The Framingham Heart Study
Franklin, S. S., Gustin, W., Wong, N. D., Larson, M. G., Weber, M. A., Kannel, W. B., & Levy, D. (1997) · Circulation · doi:10.1161/01.cir.96.1.308 · Cited by 2,321
The progression from hypertension to congestive heart failure
Levy, D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530440037034 · Cited by 2,155 · cited 1×
“Although elevated systolic blood pressure (SBP) is associated with an increased risk of developing HF, and blood pressure (BP) reduction prevents incident HF, the optimal target for BP lowering for HF prevention has been uncertain.(2) In the recently reported SPRINT trial (Systolic Blood Pressure Intervention Trial),…”

Show all 46 references

Research works printed but not linked: 2

10.1001/jama.1992.03490100085032 · DOI
10.1001/jama.1997.03550030052033 · DOI

Sorted by citations

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001062 · Cited by 992
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Macdougall, I. C., Bircher, A. J., Eckardt, K., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiß, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 489
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
House, A. A., Wanner, C., Sarnak, M. J., Piña, I. L., McIntyre, C. W., Komenda, P. V. J., Kasiske, B. L., Deswal, A. M., deFilippi, C. R., Cleland, J. G. F., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.022 · Cited by 481
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Targeting Age-Related Pathways in Heart Failure
Li, H., Hastings, M. H., Rhee, J., Trager, L. E., Roh, J. D., & Rosenzweig, A. (2020) · Circulation Research · doi:10.1161/circresaha.119.315889 · Cited by 276
Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients
Nayak, A., Hicks, A. J., & Morris, A. A. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007264 · Cited by 275
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 275
Heart failure with preserved ejection fraction
HAMO, C. E., DeJong, C., Hartshorne‐Evans, N., Lund, L. H., Shah, S. J., Solomon, S. D., & Lam, C. S. P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00540-y · Cited by 197
Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers
Triposkiadis, F. K., Xanthopoulos, A. V., Parissis, J., Butler, J., & Farmakis, D. T. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09987-z · Cited by 204
Heart failure with preserved ejection fraction: New approaches to diagnosis and management
Upadhya, B., & Kitzman, D. W. (2019) · Clinical Cardiology · doi:10.1002/clc.23321 · Cited by 158
Self-citation
Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation
Kaneko, H., Yano, Y., Itoh, H., Morita, K., Kiriyama, H., Kamon, T., Fujiu, K., Michihata, N., Jo, T., Takeda, N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052624 · Cited by 134
Self-citation
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001122 · Cited by 144
Self-citation
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Growing Heart Failure Burden of Hypertensive Heart Disease: A Call to Action
Dı́ez, J., & Butler, J. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19373 · Cited by 98
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 111
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
Kasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 81
High-Sensitivity Cardiac Troponin and New-Onset Heart Failure
Evans, J. D. W., Dobbin, S. J. H., Pettit, S., Angelantonio, E. D., & Willeit, P. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2017.11.003 · Cited by 85
Hypertension and race/ethnicity
Deere, B., & Ferdinand, K. C. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000742 · Cited by 77
Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?
Elgendy, I. Y., & Pepine, C. J. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.12.038 · Cited by 60
Primary Prevention of Heart Failure in Women
Daubert, M. A., & Douglas, P. S. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.01.011 · Cited by 61
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART
Upadhya, B., Rocco, M. V., Pajewski, N. M., Morgan, T., Blackshear, J. L., Hundley, W. G., Oparil, S., Soliman, E. Z., Cohen, D. L., Hamilton, C. A., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13073 · Cited by 44
Self-citation
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.012 · Cited by 45
Self-citation
The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention
Abovich, A., Matasic, D. S., Cardoso, R. N., Ndumele, C. E., Blumenthal, R. S., Blankstein, R., & Gulati, M. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100527 · Cited by 44
Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions
Upadhya, B., Haykowsky, M. J., & Kitzman, D. W. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9714-z · Cited by 40
Self-citation
Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016
Glynn, P. A., Ning, H., Bavishi, A. A., Freaney, P. M., Shah, S. J., Yancy, C. W., Lloyd‐Jones, D. M., & Khan, S. S. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.07.025 · Cited by 38
Effect of incentive payments on chronic disease management and health services use in British Columbia, Canada: Interrupted time series analysis.
Lavergne, M. R., Law, M., Peterson, S., Garrison, S. R., Hurley, J., Cheng, L., & McGrail, K. (2017) · Health Policy · doi:10.1016/j.healthpol.2017.11.001 · Cited by 29
Burden and challenges of heart failure in patients with chronic kidney disease. A call to action
Romero-González, G. A., Ravassa, S., González, O., Lorenzo, I., Rojas, M. A., García-Trigo, I., Garcı́a-Fernández, N., Lavilla, J., Martín-Moreno, P. L., López, B., et al. (2019) · Nefrología · doi:10.1016/j.nefro.2019.10.005 · Cited by 37
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study
Itoga, N. K., Tawfik, D. S., Montez‐Rath, M. E., & Chang, T. I. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.035 · Cited by 34
Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy
Ascher, S. B., de Lemos, J. A., Lee, M., Wu, E., Soliman, E. Z., Neeland, I. J., Kitzman, D. W., Ballantyne, C. M., Nambi, V., Killeen, A. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.735 · Cited by 33
Self-citation
Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?
Myhre, P. L., Selvaraj, S., & Solomon, S. D. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000852 · Cited by 30
Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy
Vaduganathan, M., Pareek, M., Kristensen, A. M. D., Biering‐Sørensen, T., Byrne, C., Almarzooq, Z., Olesen, T. B., Olsen, M. H., & Bhatt, D. L. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1971 · Cited by 30
Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART
Upadhya, B., Pajewski, N. M., Rocco, M. V., Hundley, W. G., Aurigemma, G. P., Hamilton, C. A., Bates, J. T., He, J., Chen, J., Chonchol, M., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16676 · Cited by 28
Self-citation
Diastolic blood pressure and risk profile in renal and cardiovascular diseases. Results from the SPRINT trial
Pinto, R. D., Pietropaoli, D., & Ferri, C. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.04.004 · Cited by 27
SPRINT Revisited: Updated Results and Implications
Wright, J. T., Whelton, P. K., Johnson, K., Snyder, J. K., Reboussin, D. M., Cushman, W. C., Williamson, J. D., Pajewski, N. M., Cheung, A. K., Lewis, C. E., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17682 · Cited by 28
Self-citation
Orthostatic Hypertension and Intensive Blood Pressure Control; Post-Hoc Analyses of SPRINT
Rahman, M., Pradhan, N., Chen, Z., Kanthety, R., Townsend, R. R., Tatsuoka, C. M., & Wright, J. T. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15887 · Cited by 24
Karma of Cardiovascular Disease Risk Factors for Prevention and Management of Major Cardiovascular Events in the Context of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Crisan, L. L., Wong, N. D., Sin, D. D., & Lee, H. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00079 · Cited by 21
Preventing new-onset heart failure: Intervening at stage A
Upadhya, B., Hegde, S., Tannu, M., Stacey, R. B., Kalogeropoulos, A. P., & Schocken, D. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100609 · Cited by 24
Self-citation
Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT
Upadhya, B., Willard, J. J., Lovato, L., Rocco, M. V., Lewis, C. E., Oparil, S., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G. P., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008322 · Cited by 21
Self-citation
The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 26
Identification of patients with preclinical heart failure with preserved ejection fraction using the H2FPEF score
Koepp, K. E., Reddy, Y. N. V., Obokata, M., Sorimachi, H., Verbrugge, F. H., Jain, C. C., Egbe, A. C., Redfield, M. M., Olson, T. P., & Borlaug, B. A. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00005-5 · Cited by 21
Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction
Hicklin, H., Gilbert, O. N., Ye, F., Brooks, J., & Upadhya, B. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01093-7 · Cited by 23
Self-citation
Intensive blood pressure lowering: a practical review
Camafort, M., Redón, J., Pyun, W. B., & Coca, A. (2020) · Clinical Hypertension · doi:10.1186/s40885-020-00153-z · Cited by 19
Phenomapping of subgroups in hypertensive patients using unsupervised data-driven cluster analysis: An exploratory study of the SPRINT trial
Yang, D.-Y. D., Nie, Z., Liao, L., Zhang, S., Zhou, H., Sun, X., Zhong, X., Du, Z., Zhuang, X., & Liao, X. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319856733 · Cited by 18
Impact of Antihypertensive Drug Class on Outcomes in SPRINT
DeCarolis, D. D., Gravely, A., Olney, C. M., & Ishani, A. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18369 · Cited by 17
The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 19
Impact of the SPRINT Trial on Hypertension Management
Ghazi, L., & Oparil, S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050416-024516 · Cited by 18
Self-citation
Hypertension and Heart Failure with Preserved Ejection Fraction
Lee, C. J., & Park, S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.002 · Cited by 20
Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction
Samson, R., & Jemtel, T. H. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021120 · Cited by 16
Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis
Molsberry, R. J., Rethy, L. B., Wang, M. C., Mehta, R. C., Lloyd‐Jones, D. M., Ning, H., Lewis, C. E., Yancy, C. W., Shah, S. J., & Khan, S. S. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18315 · Cited by 15
Self-citation
Refocusing on the Primary Prevention of Heart Failure
Jafari, L., Suen, R. M., & Khan, S. S. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00811-3 · Cited by 15
Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)
Shapiro, B. P., Ambrosius, W. T., Blackshear, J. L., Cushman, W. C., Whelton, P. K., Oparil, S., Beddhu, S., Dwyer, J. P., Gren, L. H., Kostis, W. J., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10646 · Cited by 13
Self-citation
Epidemiology of Heart Failure
Kalogeropoulos, A. P., Papadimitriou, L., & Butler, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-60987-6.00018-1 · Cited by 13
Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension
Raby, K., Rocco, M. V., Oparil, S., Gilbert, O. N., & Upadhya, B. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.16503 · Cited by 13
Self-citation
B-Type Natriuretic Peptide and Ventricular Dysfunction in the Prediction of Cardiovascular Events and Death in Hypertension
Gallagher, J., Watson, C. J., Zhou, S., Ryan, F., Ledwidge, M. T., & McDonald, K. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx153 · Cited by 13
Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community‐Dwelling Older Adults in SPRINT
Jamshidian, M. S., Scherzer, R., Estrella, M. M., Kravitz, R. L., Boxer, R. S., Tancredi, D. J., Berry, J. D., de Lemos, J. A., Ginsberg, C., Ix, J. H., et al. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19395 · Cited by 13
Modifiable risk factors predict incident atrial fibrillation and heart failure
Wong, J. A., Conen, D., Healey, J. S., & Johnson, L. (2020) · Open Heart · doi:10.1136/openhrt-2019-001092 · Cited by 12
Hypertensive Heart Failure in Asia
Rismiati, H., & Lee, H. (2021) · Pulse · doi:10.1159/000518661 · Cited by 12
Blood pressure and heart failure: focused on treatment
Chun, K., & Kang, S. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00271-y · Cited by 13
Association of Ambient Temperature and Acute Heart Failure with Preserved and Reduced Ejection Fraction
Jimba, T., Kohsaka, S., Yamasaki, M., Otsuka, T., Harada, K., Shiraishi, Y., Koba, S., Takei, M., Kohno, T., Matsushita, K., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14010 · Cited by 10
Incorporating Individual‐Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations
Ascher, S. B., Kravitz, R. L., Scherzer, R., Berry, J. D., de Lemos, J. A., Estrella, M. M., Tancredi, D. J., Killeen, A. A., Ix, J. H., & Shlipak, M. G. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.033995 · Cited by 10
The Intersection of Type 2 Myocardial Infarction and Heart Failure
McCarthy, C. P., Jones‐O’Connor, M., Olshan, D. S., Murphy, S., Rehman, S. C., Cohen, J. A., Cui, J., Singh, A., Vaduganathan, M., Januzzi, J. L., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020849 · Cited by 10
Nitroxyl Donor CXL-1020 Lowers Blood Pressure by Targeting C195 in Cyclic Guanosine-3’,5’-Monophosphate-Dependent Protein Kinase I
Kamynina, A., Guttzeit, S., Eaton, P., & Cuello, F. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.18756 · Cited by 12
Recent advances in managing primary hypertension
Leontsinis, I., Mantzouranis, M., Tsioufis, P., Andrikou, I., & Tsioufis, C. P. (2020) · Faculty Reviews · doi:10.12703/b/9-4 · Cited by 10
Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction
Upadhya, B., Lovato, L., Rocco, M. V., Lewis, C. E., Oparil, S., Cushman, W. C., Kostis, J. B., Rodríguez, C. J., Cho, M. E., Cloud, L., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.018 · Cited by 9
Self-citation
Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add?
Upadhya, B., Stacey, R. B., & Kitzman, D. W. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0913-3 · Cited by 9
Self-citation
Effect of Lower Blood Pressure Goals on Left Ventricular Structure and Function in Patients With Subclinical Hypertensive Heart Disease
Levy, P. D., Burla, M. J., Twiner, M. J., Marinica, A. L., Mahn, J. J., Reed, B. P., Brody, A., Ehrman, R. R., Brodsky, A., Zhang, Y., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa108 · Cited by 9
Gender Differences in Prognostic Markers of All-Cause Death in Patients with Acute Heart Failure: a Prospective 18-Month Follow-Up Study
Wu, X., Chen, M., Wang, K., Gao, R., & Li, X. (2019) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-019-09893-2 · Cited by 8
Burden and challenges of heart failure in patients with chronic kidney disease. A call to action
Romero-González, G. A., Ravassa, S., González, O., Lorenzo, I., Rojas, M. A., García-Trigo, I., Garcı́a-Fernández, N., Lavilla, J., Martín-Moreno, P. L., López, B., et al. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2020.06.006 · Cited by 9
Systolic Blood Pressure, Heart Rate, and Outcomes in Patients with Coronary Disease and Heart Failure
Elgendy, I. Y., Hill, J. A., Szady, A. D., Gong, Y., Cooper‐DeHoff, R. M., & Pepine, C. J. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12534 · Cited by 8
Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies
Zhang, Y., Liang, M., Sun, C., Qu, G., Shi, T., Min, M., Wu, Y., & Sun, Y. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0221-z · Cited by 7
The aging heart: exploring the role of Klotho in cardiac health/function
Daneshgar, N., Dai, D., & Grueter, C. E. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.16 · Cited by 6
Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials
Li, L., & Li, L. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000499009 · Cited by 6
Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure
Bavishi, A. A., Lloyd‐Jones, D. M., Ning, H., Vu, T. T., Yancy, C. W., Shah, S. J., Carnethon, M. R., & Khan, S. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240567 · Cited by 6
Strategic Recommendations to Bridge the Gaps in Awareness, Diagnosis and Prevention of Heart Failure in the Middle East Region and Africa
Bennis, A., Ogola, E. N., Klug, E., Skouri, H. N., Saffar, H. B. A., Ragy, H. I., Alghalayini, K. W., Alhumood, K. A., Abdelhamid, M., Yılmaz, M. B., et al. (2022) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1294 · Cited by 9
Consensus Statements from the Diabetologists & Endocrinologists Alliance for the Management of People with Hypertension and Type 2 Diabetes Mellitus
Tong, P. C.-Y., Chan, S. C.-P., Chan, W. B., Ho, K. K. L., Leung, G. T.-C., Lo, S. H.-K., Mak, G. Y. K., & Tse, T.-S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103403 · Cited by 7
Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study
Rifai, M. A., Taffet, G. E., Matsushita, K., Virani, S. S., de Lemos, J. A., Khera, A., Berry, J., Ndumele, C. E., Aguilar, D. A., Sun, C., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.118 · Cited by 5
The role of blood pressure management in stroke prevention: current status and future prospects
Narita, K., Hoshide, S., & Kario, K. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2137490 · Cited by 5
Optimal management of blood glucose, blood pressure and atrial fibrillation to reduce the risk of heart failure with preserved ejection fraction
Fan, L., Pan, J., Lin, H., Wang, C., Zhang, J., & Gu, J. (2020) · Internal Medicine Journal · doi:10.1111/imj.15006 · Cited by 5
Left Ventricular Longitudinal Strain as a Marker for Point of No Return in Hypertensive Heart Failure Treatment
Ishizu, T., Seo, Y., Namekawa, M., Murakoshi, N., Ieda, M., & Kawakami, Y. (2019) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2019.08.022 · Cited by 5
Different prognostic association of systolic blood pressure at different time points with postdischarge events in patients hospitalized for decompensated heart failure.
Yao, Y.-N., Zhang, R., An, T., Zhang, Q., Zhao, X., & Zhang, J. (2019) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2019.09.009 · Cited by 4
Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients
Oparil, S., Cushman, W. C., Johnson, K., Kitzman, D. W., Whelton, P. K., & Wright, J. T. (2018) · Circulation Research · doi:10.1161/circresaha.118.313057 · Cited by 4
Self-citation
Intensive Blood Pressure Lowering for Prevention of Heart Failure With Preserved and Reduced Ejection Fractions
Rethy, L. B., & Cohen, J. B. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009277 · Cited by 4
A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial
Li, N., Yang, Z., Yuan, Q., & Cheng, W.-L. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70098 · Cited by 3
Hypertension and heart failure: focus on high-risk populations
Palo, K. E. D. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000739 · Cited by 3
Unanswered Questions Regarding Blood Pressure Management for HF Prevention
Ramalho, S. H. R., & Shah, A. M. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0908-0 · Cited by 4
Impact of Diabetes Medication Therapy Adherence Clinic (DMTAC) appointment intervals on glycemic control in public health clinics across Perak, Malaysia
Beh, Y.-S., Gopalsamy, K., Lee, S. L. F., & Vengadasalam, V. P. P. (2022) · Malaysian Family Physician · doi:10.51866/oa1341 · Cited by 3
Self-Care Behavior in Heart Failure Patients: Impact on Cardiovascular Health Profile
Prihatiningsih, D., & Widaryati, W. (2021) · Jurnal Keperawatan · doi:10.22219/jk.v12i1.14783 · Cited by 3
Heart Failure Prevention for All
Butler, J., & Khan, M. S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.020 · Cited by 3
Role of B-Type Natriuretic Peptide in the Early Detection of Preclinical Heart Failure ― Is B-Type Natriuretic Peptide the Best Tool to Find the “Invisible Enemy”? ―
Nogi, K., & Hikoso, S. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0187 · Cited by 3
Changes in upright haemodynamics preceding heart failure events and other hospitalizations
ZALAWADIYA, S. K., Desai, A. S., Borlaug, B. A., Kiernan, M. S., Bennett, M. K., Brugts, J. J., Klein, L., & Stevenson, L. W. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag165 · Cited by 2
CHRONIC HEART FAILURE EPIDEMIOLOGY IN KAZAKHSTAN AND OTHER COUNTRIES
Bashirov, A. U. (2024) · Ulyanovsk Medico-biological Journal · doi:10.34014/2227-1848-2024-3-17-27 · Cited by 2
Interaction of Framingham risk score and sarcopenia in cardiovascular events and all-cause mortality among patients with hypertension: a prospective study based on the standard treatment of the SPRINT group
Zhang, W., Liu, Y., Feng, Z., Xiong, N., Tang, L., Zhu, X., Xue, J., Chen, W., & Dai, W. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104279 · Cited by 2
Clinical Precision in the Management of Hypertension: Improving Upon the "One-Size-Fits-All" Approach.
White, W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.075 · Cited by 2
Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
Ito, M., Matsue, Y., & Minamino, T. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2000 · Cited by 2
Expert Opinion on the Potential Role of Angiotensin Receptor-neprilysin Inhibitors in Managing Hypertension
Chopra, V. K., Jadhav, U., Ray, S., Mohan, J. C., Mehta, A., Srinivas, B., Routray, S., Prakash, V. S., Sharma, K., Balakrishnan, M. M., et al. (2026) · Journal of Indian College of Cardiology · doi:10.4103/jicc.jicc_32_25 · Cited by 1

Authors: Upadhya, B., Rocco, M., Lewis, C. E., Oparil, S., Lovato, L. C., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G., Fine, L. J., Johnson, K. C., Rodriguez, C. J., Raj, D. S., Rastogi, A., Tamariz, L., Wiggers, A., & Kitzman, D. W.
Affiliations: University of Alabama (US)
From the Cardiovascular Medicine Section (B.U., C.J.R., D.W.K.), Nephrology Section, Department of Internal Medicine (M.R.), and Biostatistics (L.C.L.), Wake Forest School of Medicine, Winston-Salem, NC; Division of Preventive Medicine (C.E.L.) and Division of Cardiovascular Disease (S.O.), Department of Medicine, University of Alabama, Birmingham; Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN (W.C.C.); Michael E. DeBakey Veterans Affairs Medical Center and Baylor College...
ORCID: Upadhya, Bharathi
Rocco, Michael
Lewis, Cora E.
Oparil, Suzanne
Cushman, William C.
Bates, Jeffrey T.
Bello, Natalie A.
Aurigemma, Gerard
Raj, Dominic S.
Rastogi, Anjay
Tamariz, Leonardo
Wiggers, Alan
Kitzman, Dalane W.
Venue: Circulation: Heart Failure
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2017-04
Volume: 10
Issue: 4
ISSN: 1941-3289 (ISSN-L)
1941-3297
DOI: 10.1161/circheartfailure.116.003613
PMC: PMC5384646
OpenAlex: W2601765095
Cited by: 118
References: 46
Citations by year: 2026: 5 · 2025: 14 · 2024: 8 · 2023: 8 · 2022: 16 · 2021: 15 · 2020: 20 · 2019: 19 · 2018: 9 · 2017: 3
FWCI: 10.79
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Circulation Heart Failure (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Department of Veterans Affairs
Amgen
Gilead Sciences
University of California
George Washington University
University of Michigan
University of Florida
University of Utah
University of Pittsburgh
National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR000073, UL1TR001064, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
University of Illinois at Urbana-Champaign
Relypsa
National Institute on Aging (R01AG020583, R01AG018915, R01AG045551, P30AG021332)
National Heart, Lung, and Blood Institute (R01HL107257, HHSN268200900040C, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
National Institute of General Medical Sciences (P30GM103337)
National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords: acute decompensated heart failure, intensive blood pressure lowering, systolic blood pressure, SPRINT trial, cardiovascular mortality, chronic kidney disease, cardiovascular disease, older adults, race and sex differences, subgroup analysis
MeSH terms: Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Female, Heart Failure, Hospitalization, Humans, Hypertension, Male, Middle Aged, Risk Factors, Time Factors, Comorbidity, Multivariate Analysis, Chi-Square Distribution, Proportional Hazards Models, Treatment Outcome, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks